Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone morphogenetic protein 3
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Parenteral
01
Overview
BMP3 recombinant protein, also known as Osteogenin, is a member of the Transforming Growth Factor-beta (TGF-beta) superfamily and is the most abundant bone morphogenetic protein in adult bone. Historically characterized as an inhibitor of osteogenic BMPs (such as BMP-2) and a modulator of activin signaling, recent research has identified its potential therapeutic role in Pulmonary Arterial Hypertension (PAH). BMP3 acts by activating the protective BMP/Smad1/5/8 signaling pathway while suppressing the pro-fibrotic TGF-β/Smad2/3 pathway, thereby inhibiting pulmonary vascular and cardiac remodeling. Currently, BMP3 is primarily available as a research-grade recombinant protein from various life science reagent suppliers and is not yet an approved proprietary clinical drug.
- Other names
- OsteogeninBone Morphogenetic Protein-3recombinant human BMP-3
02
Targets
BMP2 (Bone morphogenetic protein 2)ACVR2A (Activin receptor type 2A)BMPR1ATGFBR1ACVR2B (Activin receptor type IIB)ACVR1B (Activin A receptor type IB)BMPR1B
Beyond the preview
Go deeper on bone morphogenetic protein 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone morphogenetic protein 3.